RxDoctor Payments Data

Lindsay McComas, APRN

Family · Henderson, NVNPI 1922682863

Payments from drug & device makers

$2,406in general payments, 2019–2025

Across 69 payments — averaging $34.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$800
  • Novo Nordisk$537
  • AstraZeneca$310
  • Lilly USA, LLC$168
  • AbbVie$161
  • Boehringer Ingelheim$47
  • plus $384 from 15 others

What the payments were for

  • Consulting fees$80033%
  • Food & beverage$1,60667%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,406 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$12,525
Medicare patients
48
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$11,674
Levothyroxine Sodium70$705
Diclofenac Potassium17$518
Gabapentin23$347
Albuterol Sulfate HfaAlbuterol Sulfate14$336
Metformin Hcl30$316
Atorvastatin Calcium55$277
Rosuvastatin Calcium36$261
Losartan Potassium22$237
Metoprolol Succinate20$225
Omeprazole24$206
Amlodipine Besylate55$142
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide11$123
Lisinopril44$109
Duloxetine Hcl14$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$47$11,67412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,501 family providers in Nevada.

Other family in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →